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A pilot study of the S-MAP (Solutions for
Medications Adherence Problems)
intervention for older adults prescribed
polypharmacy in primary care: study
protocol
D. E. Patton1, J. J. Francis2, E. Clark2, F. Smith3, C. A. Cadogan4, C. Ryan5 and C. M. Hughes1*
Abstract
Background: Adhering to multiple medications as prescribed is challenging for older patients (aged ≥ 65 years)
and a difficult behaviour to improve. Previous interventions designed to address this have been largely complex in
nature but have shown limited effectiveness and have rarely used theory in their design. It has been recognised
that theory (‘a systematic way of understanding events or situations’) can guide intervention development and help
researchers better understand how complex adherence interventions work. This pilot study aims to test a novel
community pharmacy-based intervention that has been systematically developed using the Theoretical Domains
Framework (12-domain version) of behaviour change.
Methods: As part of a non-randomised pilot study, pharmacists in 12 community pharmacies across Northern
Ireland (n = 6) and London, England (n = 6), will be trained to deliver the intervention to older patients who are
prescribed ≥ 4 regular medicines and are non-adherent (self-reported). Ten patients will be recruited per pharmacy
(n = 120) and offered up to four tailored one-to-one sessions, in the pharmacy or via telephone depending on their
adherence, over a 3–4-month period. Guided by an electronic application (app) on iPads, the intervention content
will be tailored to each patient’s underlying reasons for non-adherence and mapped to the most appropriate
solutions using established behaviour change techniques. This study will assess the feasibility of collecting data on
the primary outcome of medication adherence (self-report and dispensing data) and secondary outcomes (health-
related quality of life and unplanned hospitalisations). An embedded process evaluation will assess training fidelity
for pharmacy staff, intervention fidelity, acceptability to patients and pharmacists and the intervention’s mechanism
of action. Process evaluation data will include audio-recordings of training workshops, intervention sessions,
feedback interviews and patient surveys. Analysis will be largely descriptive.
Discussion: Using pre-defined progression criteria, the findings from this pilot study will guide the decision
whether to proceed to a cluster randomised controlled trial to test the effectiveness of the S-MAP intervention in
comparison to usual care in community pharmacies. The study will also explore how the intervention components
may work to bring about change in older patients’ adherence behaviour and guide further refinement of the
intervention and study procedures.
Trial registration: This study is registered at ISRCTN: https://doi.org/10.1186/ISRCTN73831533
Keywords: Medication adherence, Polypharmacy, Theory, Behaviour change, Community pharmacists, Complex
intervention, Pilot study, Process evaluation, Technology
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Background
Polypharmacy, often defined as the use of multiple med-
icines [1], is increasingly accepted as the new paradigm
for prescribing in older adults (≥ 65 years) [2]. However,
this can give rise to challenges with adherence, a behav-
iour that is influenced by multiple factors, and has
proved resistant to interventions [3]. Increasing health-
care costs and wastage of medications resulting from
non-adherence have major financial implications for
healthcare systems. A 2012 report from the Institute for
Healthcare Informatics estimated that total avoidable
costs globally from non-adherence across 186 countries
including the United Kingdom (UK) were approximately
US$270 billion per year [4]. In addition, for patients with
long-term conditions, non-adherence may result in
treatment failures, poor disease control and reduced
quality of life [5]. To improve adherence and health out-
comes, a complex intervention with multiple interacting
components is warranted. However, previous complex
interventions have shown only limited effectiveness [3].
Furthermore, the intervention components are rarely re-
ported in sufficient detail to enable others to replicate
the studies or implement the interventions into practice.
To maximise effectiveness, the UK Medical Research
Council (MRC) recommends that complex interventions
are designed, evaluated and reported in a systematic and
rigorous way [6].
There are three key gaps in adherence research to
date. First, it is generally unclear how intervention
components have been selected for inclusion in complex
adherence interventions and, without a theoretical
underpinning, it is difficult to understand their mecha-
nisms of action [7]. This has been highlighted in a sys-
tematic review of adherence interventions delivered to
older patients prescribed polypharmacy, which reported
that only a limited number of studies used theory to
guide intervention development [7]. A theory has previ-
ously been defined by Glanz and Rimer [8] as ‘(…) a sys-
tematic way of understanding events or situations. It is a
set of concepts, definitions, and propositions that explain
or predict these events or situations by illustrating the
relationship between variables.’ Theories can facilitate
researchers’ understanding of health behaviours by firstly
explaining and predicting behaviour (how, when and
why it occurs) and secondly, helping researchers identify
key influences on behaviour that can be targeted for
behaviour change. Secondly, interventions are rarely tai-
lored to each patient’s needs, despite findings that adher-
ence problems are specific to individual patients [9, 10].
This has been illustrated in a meta-analysis conducted
by Conn and Ruppar [11] which found that only 9 out
of 771 adherence interventions delivered to adult pa-
tients (≥ 18 years) were tailored on an individual basis. In
addition, technology has been increasingly employed in
the field of adherence, for example, through the use of
electronic reminders, [12] although its role in facilitating
individual-level tailoring of complex adherence interven-
tions requires further investigation.
To address the evidence gaps noted above, a novel
theory-based tailored intervention has been systematically
developed in line with the MRC’s complex intervention
framework [6, 10]. The Theoretical Domains Framework
(TDF) of behaviour change (12-domain version) [13] was
used in a qualitative focus group study to gain an in-depth
understanding of older patients’ adherence behaviour [10].
This work led to the identification of eight key behavioural
determinants (theoretical domains) to target to improve
older patients’ adherence (e.g. ‘motivation and goals’,
‘behavioural regulation’, ‘social influences’) and 11 behav-
iour change techniques (BCTs) (e.g. ‘goal-setting’, ‘self-
monitoring’, ‘social support-unspecified’) that could be the
‘active ingredients’ of the intervention [14, 15]. These
11 BCTs were combined into an intervention which
was subsequently tested in a small-scale feasibility
study involving two community pharmacies in Northern
Ireland (NI) with five patients recruited per pharmacy
(previously known as the IDentification of Medication
Adherence Problems (ID-MAP) intervention; https://doi.
org/10.1186/ISRCTN17966504, [16]). Community phar-
macists were selected to deliver this intervention due to
their accessibility to patients in the primary care setting
and frequency of contact with patients [10]. The
intervention was guided by a paper-based adherence
assessment tool that was designed to assist pharma-
cists in identifying adherence problems and selecting
tailored solutions (i.e. BCTs) to deliver to patients. Al-
though this feasibility study demonstrated the usability
and acceptability of the intervention from the viewpoint of
older patients and pharmacists, it highlighted the need for
modifications to the intervention, such as an electronic as-
sessment tool to guide intervention tailoring, and to study
procedures. Consequently, the study described in the
current protocol aims to test a refined version of the inter-
vention—Solutions for Medications Adherence Problems
(S-MAP) intervention—and modified study procedures in
a larger sample of community pharmacies in two geo-
graphical areas (NI and London, England) as part of a
non-randomised pilot study. The objectives of the study
are to
1. Test the feasibility of methods for recruiting and
retaining community pharmacies and patients
2. Develop a web-application (app) to support
intervention delivery including an electronic version
of the adherence assessment tool to guide
intervention tailoring
3. Design and deliver a training programme for
pharmacy staff
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4. Deliver the S-MAP intervention in the community
pharmacy setting in NI and London
5. Undertake a process evaluation (exploring fidelity,
acceptability and mechanisms of action)
6. Explore the appropriateness and suitability of
selected outcome measures
This pilot study will provide evidence to guide the de-
cision on whether to proceed to a definitive cluster RCT
(cRCT) to explore effectiveness of the S-MAP interven-




This study is a multi-centre non-randomised pilot
study consisting of an intervention group only (i.e. no
control group). Ethical approval was granted by the
Office of Research Ethics Committees for Northern
Ireland (REC reference: 17/NI/0193) and the Health
Research Authority (IRAS ID: 234121). The informa-
tion reported in this protocol follows recommenda-
tions from the SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) 2013
statement [17]. A completed SPIRIT checklist can be
found in Additional file 1.
Pharmacy sampling and recruitment
The study will be carried out in 12 community pharma-
cies in the UK. Maximum variation sampling, a form of
purposive sampling that aims to identify a diverse range
of participants, will be employed. Six pharmacies will be
selected from the five Health and Social Care Trusts
(HSCT) areas in NI and six pharmacies selected from six
(out of 32) Clinical Commissioning Groups (CCGs) in
London. To ensure variation in the sample, the six
CCGs will be selected from areas of both low and high
levels of social deprivation in London. A single UK-wide
measure of social deprivation is not currently readily
available [18]. Therefore, the Index of Multiple
Deprivation (where a rank of 1 indicates the most de-
prived area and 9 indicates the least deprived area) will
be employed to assess social deprivation levels of areas
served by the community pharmacies in London. The
NI Multiple Deprivation Measure (where 1 indicates the
most deprived area and 890 indicates the least deprived
area) will be employed for NI-based pharmacies. As this
data will solely be used for reporting the level of vari-
ation in the sample (and not for data analysis purposes)
no adjustment techniques will be used.
This study also aims to achieve variation in the sample
by selecting pharmacies in both rural and urban areas in
NI (data source: [19]) and including pharmacies that are
independently owned or part of small or large chains.
The community pharmacy landscapes differ somewhat
in NI and England (i.e. there are very few chains com-
prising > 100 pharmacies in NI [20], whereas this is
more common in England [21]). For that reason, region-
specific definitions will be used for categorising pharma-
cies as being independently owned or part of small or
large chains (see Table 1).
Pharmacies will be contacted initially via a letter seek-
ing expressions of interest (via a reply slip). A researcher
will contact those expressing interest to provide further
details. If insufficient reply slips are returned, the re-
searcher will telephone pharmacies to try and recruit the
required number. If required, the research team will use
personal contacts, local networks and social media to ad-
vertise the study and enhance recruitment.
In order to meet the inclusion criteria, community
pharmacies must have a private consultation area, Wi-
Fi/printing facilities and be registered with the appropri-
ate professional body (e.g. General Pharmaceutical
Council). Interested pharmacists will be provided with
an information sheet and consent form and a researcher
will arrange a meeting to discuss participation. Multiple
pharmacists in a single pharmacy can participate pro-
vided they each give informed consent. All pharmacists
must be employed within the pharmacy on a regular
basis (i.e. not a locum pharmacist) and undertake train-
ing in study procedures and intervention delivery (see
the ‘Training package overview’ section below). Partici-
pating pharmacists will be provided with a certificate of
participation for continuing professional development
purposes and each pharmacy will be offered an honorar-
ium for participation [£500 (NI)/£600 (London)]. As a
further incentive, pharmacies will receive an additional
£30 for each patient to whom they deliver the interven-
tion (up to a maximum of £300). Where possible, phar-
macists will delegate pre-specified tasks (e.g. recruitment
of patients) to pharmacy support staff, although pharma-
cists will be responsible for delivering the intervention
to patients. In order to participate in the study, support
staff must have completed, as a minimum, an accredited
Medicines Counter Assistant course (or equivalent).
They will be given a study information sheet and asked
to provide written informed consent and undertake
training in study procedures (see the ‘Training package
overview’ section).
Table 1 Definitions for pharmacy types in Northern Ireland (NI)
and London, England
Type of pharmacy Definition for NI [20] Definition for London [21]
Independently owned 1–3 pharmacies 1–5 pharmacies
Small chain 4–9 pharmacies 6–99 pharmacies
Large chain ≥ 10 pharmacies ≥ 100 pharmacies
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Patient screening and recruitment
There will be two stages to screening patients for partici-
pation in the study. In stage 1, patient medication re-
cords (PMR) will be used to identify patients aged 65
years or older who are prescribed ≥ 4 regular medicines
(excluding ‘when required’ dosing or variable dosing
medications e.g. take one or two tablets daily) and live in
their own home (i.e. not a care home). Twelve months
of dispensing data must be available on the pharmacy’s
PMR system for the patient to be eligible (for outcome
assessment purposes, see the ‘Outcome data collection’
section). Patients who are prescribed medications for the
treatment/management of dementia (e.g. donepezil) or
who are unable to provide informed consent will be ex-
cluded as the intervention has not been designed to ac-
count for the additional challenges these patients are
likely to face.
Following this initial screen, in stage 2, patients will be
approached in the pharmacy by trained pharmacy staff
or mailed letters inviting them to complete an adherence
screening questionnaire (and provide consent for this ac-
tivity). The screening questionnaire consists of two self-
reported measures of adherence [validated Medication
Adherence Reporting Scale-5 item (MARS-5) and one
item from the Lu et al. instrument] [22, 23]. This aims
to identify patients who have adherence difficulties, as
research has shown that interventions are more effective
when targeted at non-adherent patients [11]. Only pa-
tients who are identified as non-adherent via the self-
report measure will be invited to take part in the study
(questionnaire scoring information available from au-
thors upon request). Pharmacy staff will also confirm
that the patient only attends their pharmacy for regular
medications. Patients who attend multiple pharmacies
will be excluded as complete dispensing records are re-
quired for outcome assessment. Eligible patients will be
invited to attend their first session of the intervention in
the pharmacy (see the ‘Intervention delivery’ section) at
which point the pharmacist will ensure informed con-
sent has been given.
This pilot study does not aim to assess effectiveness.
Therefore, a sample size calculation has not been under-
taken. Each pharmacy will be asked to recruit ten older
patients who meet the eligibility criteria listed above as
this has been deemed sufficient (based on the extensive
experience of the research team and experience in other
similar studies) to meet the objectives of this pilot study
as described above (120 patients in total). To enhance
recruitment, the study will be advertised to patients via
flyers/posters displayed in the pharmacy, or on their so-
cial media platforms. This study aims to pilot different
strategies, such as approaching patients in the pharmacy
or via letter, to identify the most feasible strategy for
patient screening and recruitment. At the time of
submission of this paper, patient recruitment had com-
menced and an amendment to the study screening pro-
cesses described above had been implemented. Details of
the amended procedures are provided later under the
‘Study amendments’ section.
Intervention specification
As referred to above, previous qualitative work under-
taken by the research team [10] identified 11 BCTs (see
Table 2) that were selected to be the proposed ‘active in-
gredients’ of the patient-targeted intervention and tested
in a small-scale feasibility study [16]. Following this, a
BCT validation exercise was conducted to ensure an ac-
curate specification of the intervention (unpublished
work). This involved coding descriptions of the interven-
tion content using the BCT Taxonomy version 1 [24], by
four members of the research team (SC, CC, JF, EC)
who were not directly involved in the original mapping
from TDF domains to BCTs. Four additional BCTs were
identified in this exercise (see Table 2) and have been
added to the intervention specification, bringing the total
number of BCTs in the S-MAP intervention to 15.
Web-application (app) development overview
In the previous feasibility study, all intervention and study
materials were paper-based which was time-consuming,
burdensome and sometimes impractical in a busy health-
care environment [16]. To overcome this in the current
pilot study, pharmacies will be provided with iPads to as-
sist with intervention delivery. A web-application (app)
will be developed (accessible on the iPad) that will act as a
decision support tool during the intervention. The app
will support pharmacists in identifying adherence prob-
lems and mapping these to potential adherence solutions
(i.e. BCTs). Doing so will assist the tailoring of the inter-
vention content to each individual patient’s needs.
Pharmacists will be trained to use the app as part of the
above-mentioned training package. For practical reasons,
paper-based forms will be used for study procedures (e.g.
study information sheets, questionnaires).
Intervention delivery
Research has shown that older patients’ reasons for non-
adherence are often individual and, therefore, it would
be inappropriate, or unnecessary, to deliver all 15 BCTs
to each patient [10]. Consequently, the S-MAP interven-
tion is intended to be a ‘personalised’ intervention
whereby the intervention is tailored to the individual
needs of each patient. Some BCTs, such as ‘problem-
solving’, ‘self-monitoring’ and ‘feedback on behaviour’,
are potentially relevant to all patients, irrespective of
why they are non-adherent. For example, a brief self-
monitoring period using a medication diary could act to
help establish new routines (for patients who are
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Table 2 Behaviour change techniques (BCTs) that will be delivered to older patients as part of the S-MAP intervention
Behaviour change
technique (BCT)
Specification for BCT delivery as part of the S-MAP intervention Context in which the BCT be
delivered? (‘core’ or ‘optional’ BCT)a
Problem-solvingb The pharmacist will prompt the patient to think of factors that influence
their medication-taking behaviour (e.g. being away from home) and
encourage the patient to select solutions to overcome any barriers or act
as facilitators of the behaviour.
All non-adherent patients (core)a
Self-monitoring Patients will be asked to monitor their medication use on a daily basis




Based on a review of the patient’s medication diary, the pharmacist will
provide feedback on the patient’s individual adherence at follow-up
sessions. For example, the pharmacist might say, ‘You managed to take
all of your medicines on weekdays but missed some at weekends’.
Social support
(unspecified)
The pharmacist will provide, or identify others (e.g. family) who can provide,
general encouragement to patients with regards to taking their medications
as prescribed.
Social rewardb The pharmacist will praise patients who have improved adherence and
encourage continued adherence.




The pharmacist will assist patients in setting and writing down an
adherence-related goal that specifies a behaviour that will be done. For
example, ‘I will use my preventer inhaler every day’.
Patients deemed non-adherent at
follow-up sessions (optional)a
Action planning A personalised plan to achieve the goal(s) set will be developed collaboratively
by the patient and pharmacist. This plan can include the time, place or how
often the behaviour is performed. For example, ‘When it is 9 pm and I am
brushing my teeth, then I will take my simvastatin’.
Review of
behaviour goal
The pharmacist and patient together will review the adherence-related goal
set at the previous session and re-set or modify this. For example, if the
previous goal (‘I will use my preventer inhaler every day’) was too ambitious,
then the goal could be modified to one that is more achievable (‘I will use my
preventer inhaler at least six days each week’).
Social support
(practical)b
Where necessary, additional practical support from family/friends or other
healthcare professionals will be arranged. For example, family members
could help the patient with organising medications into a weekly pill
reminder box.
Tailored based on adherence




The pharmacist will assist patients who have low motivation in setting and
writing down a goal that focuses on the positive outcomes of adherence. For




The pharmacist and patient together will review the outcome goal that was
set at the previous session. The goal will be re-set or modified. For example,
it might be that the original outcome goal is not achieved by better adherence





The pharmacist will inform patients about the benefits of taking their
medications as prescribed and the risks associated with non-adherence. Patient
leaflets have been designed as part of the intervention to facilitate discussions
around medication concerns and generic medications and will be given to
patients as part of the intervention if deemed appropriate.
Prompts and cues The pharmacist will ask about the contexts in which forgetting is more likely
and make suggestions about possible prompts. For example, a patient who
routinely forgets their bedtime medications could benefit from linking
medication taking to brushing their teeth.
Restructuring the
physical environment
Patients may be advised to change where they store their medications or
alter their home environment to facilitate adherence. For example, patients




For patients who have difficulties with any aspect of the medication
packaging or formulation/regimen and would like support, the pharmacist
will provide more appropriate packaging or recommend changes to the
prescriber. For example, if the patient has difficulty opening child-resistant
bottle caps, then the pharmacist could supply non-child resistant bottle caps.
a‘Core’ BCTs are recommended for delivery to all non-adherent patients in the study. ‘Optional’ BCTs are delivered based on each individual patient’s
needs including the underlying reasons for non-adherence and improvements in adherence scores
bNew BCT labels identified from the validation coding exercise (unpublished work)
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unintentionally non-adherent), reinforce the importance
of adherence or act as a platform for pharmacists to
engage patients (who are intentionally non-adherent) in
discussions about the underlying reasons for non-
adherence. These BCTs have been termed ‘core’ BCTs
[16]. Some BCTs are unlikely to benefit all patients, for
example, a patient who intentionally decides to stop tak-
ing their medication because they are worried about po-
tential side effects is unlikely to benefit from the BCT
‘prompts and cues’ which addresses the problem of for-
getting. Alternatively, a patient who is already aware of
the health consequences of non-adherence, but simply
forgets to take medications, is unlikely to benefit from
the BCT ‘health consequences’. These types of BCTs
will, therefore, be recommended for delivery based on
an assessment of patients’ underlying reasons for non-
adherence and reported adherence levels which will be
guided by the app. For example, the BCT ‘social reward’
(i.e. verbal praise) will only be delivered to those patients
in whom there has been an improvement in adherence.
These have been termed ‘optional’ BCTs [16]. Table 2
indicates the context in which each BCT will be deliv-
ered as part of the intervention and whether it has been
deemed a ‘core’ or ‘optional’ BCT.
Adherence problems for patients prescribed multiple
medications to treat a variety of conditions can range in
severity. Hence, patients require varying levels of sup-
port and contact with healthcare professionals [25].
Findings from the previous feasibility study have indi-
cated that a pre-defined number of sessions with the
pharmacist may not be optimal for this group of patients
[16]. Hence, the S-MAP intervention will be delivered in
up to four sessions over a 4-month period with the
number of sessions tailored to each patient’s needs. A
flow chart detailing the session flow of the intervention
is provided in Fig. 1.
Prior to session 1, the pharmacist will obtain a list of
medications prescribed to the patient using the PMR
and contact the patient’s general practitioner (GP) for
clarification, if required. At session 1, the pharmacist will
confirm the medication list with the patient and under-
take an adherence assessment, using the app. This as-
sessment will explore seven areas: (1) medication
knowledge, (2) routine/organisational barriers, (3) prac-
tical barriers, (4) level of social support, (5) forgetfulness,
(6) level of motivation and (7) cases of intentional non-
adherence. This assessment tool was designed based on
the previous TDF-based qualitative work [10] and modi-
fied based on feedback from participants in the previous
feasibility study [16]. Identified adherence problems will
be automatically mapped to recommended adherence
solutions (i.e. BCTs) and, using a patient-centred (i.e.
collaborative) approach, the pharmacist and patient will
discuss which solution(s) would be most suitable. As
part of the intervention, all patients will be offered a
medication diary (BCT ‘self-monitoring’) which will con-
tain details of their prescribed medications. A review
session will be scheduled for 1–2 weeks later.
At session 2, the pharmacist will review the patient’s
medication diary (if used), provide feedback on this
(BCT: feedback on behaviour) and then re-assess adher-
ence using the self-report measures used previously for
screening. If adherence has improved, praise will be
given by the pharmacist (BCT: social reward). No other
BCTs will be delivered or recommended (unless add-
itional support is requested) and the pharmacist will
Fig. 1 Overview of the session flow in the S-MAP intervention
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agree to contact the patient by telephone in 6–8 weeks
for another review. If the patient is non-adherent at ses-
sion 2, then the pharmacist will deliver or recommend
additional BCTs and schedule a review session in the
pharmacy in 6–8 weeks.
Session 3 may be conducted via telephone or in the
pharmacy, depending on the patient’s adherence and
need for more support at session 2. The pharmacist will
review the patient’s diary if used (pharmacy sessions
only) and re-assess adherence. If the patient is deemed
adherent, then praise will be given and no other BCTs
will be delivered. Non-adherent patients will be offered
more support and then invited back for another review
session in 6–8 weeks. Patients who are telephoned for
session 3 and deemed non-adherent will be invited to at-
tend the pharmacy as soon as possible and offered more
support (and further review in 6–8 weeks).
Session 4 will only be offered to those patients who
were deemed non-adherent (or required more support)
at session 3. At the final intervention session (session 3
or 4 depending on adherence), patients will be advised
to maintain contact with the pharmacy should they re-
quire ongoing support.
The app will guide each of the sessions and act as an
intervention summary by allowing data on the sessions
between patients and pharmacists (e.g. solutions recom-
mended) to be captured. It is anticipated that sessions
will last between 20 and 30 min, although this study will
help to confirm this. GP practices will be informed
about the study and may be contacted following the ses-
sions if the issues cannot be resolved by the pharmacist
(e.g. where a change to the prescription is recommended
to improve adherence).
Training package overview
A brief training package was delivered as part of the pre-
vious feasibility study [16] in a face-to-face session (1.5
h) at each pharmacy and found to be useful. However,
additional training needs were identified (e.g. the need
to practise elements of intervention delivery). To further
explore the training needs of community pharmacists, in
the context of providing adherence support to older
adults, interviews (n = 15) and a survey of community
pharmacists (n = 143) were conducted in NI as part of a
linked study [16]. This research found that pharmacists
required additional training to equip them with the skills
required to deliver key components of the S-MAP inter-
vention (e.g. goal-setting BCTs). In view of these find-
ings, a modified training package will be developed and
delivered in a more interactive format for this pilot
study. This will consist of a 1-day workshop held in each
of the two locations (a ‘distance learning’ package will be
developed for pharmacists who are unable to attend).
The training workshop will include didactic sessions that
provide an overview of the intervention and study proce-
dures as well as interactive sessions and activities (e.g.
video demonstrations, role plays) (further information
about the training workshop is available from the au-
thors upon request). The training workshops will be
audio-recorded (with consent) and pharmacists will have
the opportunity to provide feedback on the training via a
brief survey. A secure online discussion forum will be
set up (on the distance learning platform Moodle) to
allow study pharmacists to communicate directly with
each other following the training and provide ongoing
support for the study duration. Participating pharmacy
support staff will be required to undertake training in
study procedures via a ‘distance learning’ package and
site visits by a researcher.
Outcome data collection
Outcome data will be collected at baseline (following pa-
tient recruitment and pre-session 1) and at 6 and 12
months follow-up from baseline. The primary outcome
of interest is medication adherence, which the literature
recommends should be measured using multiple mea-
sures, one of which should be objective [26]. Therefore,
adherence will be objectively measured using dispensing
data from each pharmacy’s PMR to calculate each
patient’s Medication Possession Ratio (MPR) and Daily
Polypharmacy Possession Ratio (DPPR) [27, 28] in the
12months pre- and post-session 1. Both measures at-
tempt to examine the amount of medication that the
patient has available over the defined period (as a surro-
gate for consumption). The two adherence question-
naires (MARS-5 [22] and one item adapted from Lu
et al. [23]) used for screening will be used as a baseline
measure and will be administered again at 6 and 12
months (via postal questionnaire). The adapted question
from Lu et al. asks patients to pick one of six options
ranging from very poor to excellent in response to the
following statement: ‘Many people are not able to take
all of their medicines as prescribed by their doctor. Rate
your ability to take all of your regular prescribed medi-
cines in the last month’ [23].
In addition to measuring adherence, the most recent
Cochrane review on adherence interventions by Nieuwlaat
et al. [3] recommends the inclusion of appropriate clinical
and humanistic outcomes that are important to patients.
Therefore, health-related quality of life (HRQoL) and un-
planned hospitalisations, both of which have been selected
to be part of a core outcome set for research conducted
with older people prescribed several medications [29], will
be measured in this study. The EQ-5D-5 L questionnaire
(UK version) will be administered as a self-report measure
of HRQoL [30]. Unplanned hospitalisations, resulting in
an overnight stay in a hospital, will be measured via self-
report from patients using a tool developed specifically for
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this study (which can be obtained from the authors upon
request). This pilot study will also be used to determine
whether it is feasible to cross-check this self-reported in-
formation on hospitalisations based on GP records. The
questionnaires (measuring HRQoL and hospitalisations)
will be administered at baseline by pharmacy staff (pre-
session 1) and again at 6 and 12months’ follow-up via
postal questionnaire (along with the adherence measures).
Patients will be telephoned as a reminder and given the
opportunity to complete the questionnaires via telephone
if necessary.
Analysis in relation to the study outcome measures will
be descriptive as the study is not seeking to assess inter-
vention effectiveness. Rather, the purpose is to test the
feasibility of the data collection procedures in advance of a
cRCT. Descriptive statistics (e.g. mean, standard deviation)
will be conducted using SPSS (version 25.0).
Process evaluation and progression criteria
A process evaluation will be embedded in the study to
assess: (1) training fidelity and acceptability, (2) interven-
tion fidelity and acceptability from the viewpoint of
patients and pharmacists and (3) the mechanism of ac-
tion of the intervention. Firstly, it will explore if the
training is delivered by the researchers and received by
the pharmacists as intended (training fidelity) and evalu-
ate how acceptable this is to pharmacists. This will be
assessed by audio-recording training workshops and a
post-workshop feedback survey. Secondly, it will explore
if the intervention was delivered by pharmacists (fidelity
of intervention delivery) and received by patients as
intended (fidelity of intervention receipt), by audio-
recording, transcribing and coding all sessions held in
the pharmacy for one patient (with their consent) per
pharmacy. At the end of intervention delivery to pa-
tients, semi-structured qualitative interviews will be con-
ducted with the recruited pharmacists to review
acceptability of the intervention. Pharmacists will also be
asked about their views on the training and support pro-
vided by the research team and study procedures. Inter-
views will be completed face-to-face at a convenient
location (e.g. pharmacy site) or via telephone, audio-
recorded (with consent) and transcribed verbatim. Pa-
tients will also be given a short post-intervention survey
to complete to explore their views on the intervention
including the support received from pharmacists, any
materials provided during sessions, perceived benefits
(or lack thereof) and their overall experience. The feed-
back from pharmacists and patients will inform future
refinements to the intervention and study procedures in
advance of a larger trial. Finally, the process evaluation
will seek to identify how the intervention might work to
bring about change in adherence behaviours (i.e. the
mechanism of action) using qualitative and quantitative
data collected from pharmacists and patients including
audio-recordings of patient sessions, feedback interviews
and surveys. Audio-recordings of patient sessions and
post-intervention delivery feedback interviews with phar-
macists will be coded to explore which BCTs were deliv-
ered by pharmacists and received by patients and which
were most helpful in improving adherence. We will also
explore, from session audio-recordings, any patient-
reported changes in barriers to adherence (e.g. changes
to medication knowledge, routine or side effects). As
part of the post-intervention feedback survey, patients
will be asked if they received a range of resources (e.g.
the medication diary) and the usefulness of these re-
sources on a scale of 1–5. This quantitative data (from
patient surveys) and qualitative data (from patient ses-
sion and pharmacist interview audio-recordings) will
provide an indication as to the potential mechanism(s)
of action of the intervention.
This pilot study will provide an indication as to
whether a definitive cRCT of the S-MAP intervention is
warranted and whether further modifications are re-
quired. The use of ‘Stop, Amend, Go’ progression cri-
teria (also known as continuation criteria) for pilot
studies has recently been advocated by Avery et al. [31].
The progression criteria that will be used in this study
for decision-making purposes are presented in Table 3.
The study will not proceed to a full-scale cRCT if one
or more of the concepts in Table 3 meet the ‘Stop’ cri-
terion unless there are clear and potentially modifiable
contextual issues that account for the findings and/or
the study procedures/intervention design could be
amended to overcome any issues. Further feasibility and
pilot testing may be deemed appropriate as an alterna-
tive to advancing directly to a cRCT if issues are identi-
fied, but it is unclear whether these are modifiable and if
other aspects of the study and intervention show prom-
ise. The trial will proceed to a cRCT, with caution, if
there are issues that can be remedied (i.e. one or more
of the concepts in Table 3 meet the ‘Amend’ criteria). If
there are no issues for concern that could potentially
threaten the future success of the trial (i.e. all concepts
in Table 3 meet the ‘Go’ criterion), then a future cRCT
will be planned. If there is insufficient evidence available
from the data to support a judgement for any of the con-
cepts listed, then the ‘Stop, Amend, Go’ criteria will not
be applied. For example, if it is unclear from the session
audio-recordings whether patients engaged with or used
the delivered/recommended BCTs, then the ‘enactment
of treatment principles’ concept will not contribute to
the final decision on whether to proceed to a cRCT.
Data management and monitoring
All participants will receive a unique study ID number
and data will be anonymised/pseudonymised (e.g.
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questionnaires and interview transcripts) as appropriate.
No directly identifiable patient information (e.g. names,
dates of birth) will be recorded on the app in order to
protect patient confidentiality. Lockable storage boxes
will be provided to each pharmacy site for securing
study paperwork. Following intervention delivery, the re-
searcher will collect study documentation from pharma-
cies, after which the research team will assume
responsibility for its safekeeping. All hardcopy data (e.g.
consent forms) will be stored in locked fire-resistant
Table 3 Progression criteria (‘Stop’, ‘Amend’, ‘Go’) for the S-MAP pilot study
Concept Data source(s) Progression criteria
Stop (unless there are clear and
modifiable contextual or design





held by the research
team
If ≤ 5 pharmacies are recruited
within 8 months
If 6–9 pharmacies are recruited
and/or it takes longer than
predicted (> 4–6 months)
If ≥ 10 pharmacies are recruited




by the research team
If ≤ 49% of pharmacies are
retained for the required period
If 50–79% of pharmacies are
retained for the required period
If ≥ 80% of pharmacies are






If ≤ 59 patients are recruited
within 6 monthsb or alternativelyc
if ≤ 49% of pharmacies achieve a
monthly recruitment rate of two
patients per month for any three
consecutive months
If 60–95 patients are recruited
within 6 monthsb or alternativelyc
if 50–79% of pharmacies achieve
a monthly recruitment rate of two
patients per month for any three
consecutive months
If ≥ 96 patients are recruited
within 6 monthsb or alternativelyc
if ≥ 80% of pharmacies achieve a
monthly recruitment rate of two
patients per month for any three
consecutive months
Patient retention Study documentation
completed by
pharmacy staff
If ≤ 49% of patients are retained
for the required period
If 50–79% of patients are retained
for the required period
If ≥ 80% of patients are retained







If ≤ 49% of planned training
components are delivered by
the researchers
If 50–79% of planned training
components are delivered by the
researchers
If ≥ 80% of planned training








If ≤ 49% of delivered training
components are received by
pharmacists as intended
If 50–79% of delivered training
components are received by
pharmacists as intended
If ≥ 80% of delivered training




If ≤ 49% of pharmacists report
that they feel prepared to take
part in the study
If 50–79% of pharmacists report
that they feel prepared to take
part in the study
If ≥ 80% of pharmacists report
that they feel prepared to take






If ≤ 49% of pharmacists report
that the training day was
acceptable
If 50–79% of pharmacists report
that the training day was
acceptable
If ≥ 80% pharmacists report that







If ≤ 49% of BCTs are delivered
to patients when appropriate
If 50–79% of BCTs are delivered
to patients when appropriate
If ≥ 80% of BCTs are delivered







If ≤ 49% of delivered BCTs are
received by patients as intended
If 50–79% of delivered BCTs are
received by patients as intended
If ≥ 80% of delivered BCTs are







If ≤ 49% of pharmacists report
that the intervention was
acceptable
If 50–79% of pharmacists report
that the intervention was
acceptable
If ≥ 80% pharmacists report that







If ≤ 49% of patients report that
the intervention is acceptable
If 50–79% of patients report that
the intervention is acceptable
If ≥ 80% of patients report that





a sample of patient
sessions
If ≤ 49% of patients engaged
with (or used) the delivered
(or recommended) BCTs
If 50–79% of patients engaged
with (or used) the delivered (or
recommended) BCTs
If ≥ 80% of patients engaged
with (or used) the delivered
(or recommended) BCTs




If ≥ 50% of the main outcome
data are missing
If 21–49% of the main outcome
data are missing
If ≤ 20% of the main outcome
data are missing
aThis includes aspects of the study/intervention that may be modified in advance of a larger definitive trial
bTo enable sufficient time to assess patient recruitment procedures, the patient recruitment period may be extended up to a maximum of 12 months (post-
training) if major ethics amendments are made during the pilot study
cThe alternative ‘rate-related’ criterion recognises that successful patient recruitment procedures may take some time to establish
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storage cabinets and electronic data securely stored on
encrypted and password-protected computers and
servers. At the end of the study, data will be retained for
5 years before being destroyed. Any data published as a
result of this study will not be attributable to individual
patients, pharmacy staff or their affiliated community
pharmacy/company. Only a subset of the research team,
who are responsible for data analysis, will have direct ac-
cess to confidential data collected.
A Project Advisory Group (PAG), consisting of two
patients and two pharmacy representatives, will assist
the research team during the course of this pilot study
by advising and commenting on the study design and
progress. Any amendments to the protocol will be com-
municated to relevant parties (e.g. pharmacy sites,
Research Ethics Committee, trial registries) and reported
in the final published manuscript. The findings of this
study will be communicated to all participants, pub-
lished in relevant journals and presented at conferences.
Discussion
The aim of this pilot study is to test the feasibility of the
S-MAP intervention and study procedures in community
pharmacies in NI and London. This will help to establish
whether to proceed to a cRCT to assess intervention ef-
fectiveness. The intervention aims to improve older pa-
tients’ adherence to multiple medications through a
tailored intervention that will be guided by a web-app
which will be accessed via iPads. This study will also assess
the feasibility of measuring outcomes (unplanned hospita-
lisations and HRQoL) that were included in a core out-
come set for research conducted with older adults
prescribed multiple medications in primary care [29].
Community pharmacists will be trained to deliver the
intervention at a 1-day interactive workshop. This study
will explore how acceptable this is to pharmacists and
whether this equips them with the skills required to
deliver the intervention. Findings from a recent meta-
analysis conducted by Conn and Ruppar [11] have sup-
ported the decision to select community pharmacists as
the intervention provider as adherence interventions de-
livered by pharmacists were shown to be more effective
than those delivered by other healthcare professionals
(nurses, clinicians). As referred to previously, this meta-
analysis also highlighted that tailoring of adherence in-
terventions on an individual basis is uncommon. Thus,
this community pharmacy-based study will add to the
literature by testing how the use of an app can guide this
tailoring process which involves mapping adherence
problems to the solutions most likely to bring about pa-
tient behaviour change. This systematic approach aims
to ensure consistency in the delivery of intervention
components and ultimately facilitate intervention repli-
cation in other clinical settings.
Previous research into adherence interventions has
seldom utilised theory to better understand the underlying
reasons for the success and failure of interventions [7].
We believe this is the first study to adopt a theory-based
approach, using the Theoretical Domains Framework, to
develop a tailored app-guided intervention to improve
older patients’ adherence to multiple medicines. The
embedded process evaluation will explore potential mech-
anisms of action of the intervention and provide insight
into which components are likely to be effective or
ineffective and the potential reasons why.
Study status
This study was registered at ISRCTN (https://doi.org/10.
1186/ISRCTN73831533) on 12 January 2018. At the time
of submission of this study protocol (version 5.0; date, De-
cember 7, 2018), the app development phase was
complete and staff from 12 community pharmacies (15
pharmacists, 7 support staff) had been recruited and
trained. Thirty-eight patients had also been recruited and
intervention delivery commenced.
Study amendments
A key objective of this study is to test approaches to the
recruitment and retention of patients. The patient
screening strategy has therefore been amended during
the patient recruitment phase of the study (ongoing at
the time of submission) based on feedback from partici-
pating pharmacists and the PAG. Pharmacists were
reporting that the self-report adherence measure used
for screening may not be an accurate reflection of their
own assessments of patients’ adherence behaviour. This
is supported by research showing that subjective self-
report measures often overestimate adherence, in com-
parison with more objective measures (e.g. dispensing
records) [32]. Therefore, the self-report measure has
been removed from the eligibility screening process and
instead, pharmacists will identify non-adherent patients,
using pharmacy dispensing records or based on discus-
sions with them. The adherence measures will now be
administered along with the EQ-5D-5L and hospitalisa-
tions questionnaires after recruitment into the study (i.e.
pre-session 1).
Some pharmacist participants have also reported that
they feel patients aged 50 years and over, with long-term
conditions, could also benefit from participation in this
research. In addition, ethnic minority groups may be at a
particular disadvantage from the age limit of 65 years as
they are commonly diagnosed with conditions, such as
cardiovascular conditions and diabetes, much earlier [33,
34]. Early intervention and developing positive adher-
ence behaviours when patients are newly diagnosed may
have health benefits that last into old age and conse-
quently benefit an ageing population. Therefore, the age
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limit for participation has been lowered to 50 years. This
is in line with the work of UK-based ageing charities
(AgeNI, AgeUK) which support patients aged ≥ 50 years
[35, 36]. These amendments have received ethical
approval.
To allow sufficient time to assess new study proce-
dures, the patient recruitment period was extended until
31 July 2019. As a result, the 12-month follow-up time
point has been removed to ensure the study can be com-
pleted on time with the funding provided. Data will still
be collected at 6 months post-baseline as planned.
Additional file
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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